Market Overview:
The global equine rabies immunoglobulin (ERIG) market is expected to register a CAGR of 5.8% during the forecast period, 2018-2030. The ERIG market is segmented on the basis of type, application and region. On the basis of type, the ERIG market is segmented into 1500IU, 1000IU, 400IU and other segments. The 1500IU segment is expected to account for a major share in terms of revenue in 2018 and is projected to maintain its dominance during the forecast period as well. This can be attributed to factors such as rising incidences of rabies across different geographies and increasing demand for preventive measures against rabies infections in horses. On the basis of application, category II exposure accounted for a major share in terms of revenue in 2017 and this trend is projected to continue during the forecast period as well.
 Industry Outlook.svg)
Product Definition:
Equine Rabies Immunoglobulin (ERIG) is a purified, equine-derived antibody preparation used to prevent rabies in humans. It is made from the serum of horses that have been vaccinated against rabies and subsequently tested negative for the virus. ERIG neutralizes rabies virus before it can infect cells. It is given as an injection into muscle tissue, usually in the arm or buttocks.
1500IU:
1500IU is a subcutaneous immunoglobulin replacement therapy used in the treatment of immune-mediated diseases and as an anti-inflammatory drug. It has been observed that patients suffering from chronic inflammatory conditions have low levels of Immunoglobulin (IG) in their blood. The Equine Rabies Immunoglobulin (ERIG) market is expected to witness growth due to rising incidences of rabies infection worldwide, which may lead to death if not treated on time.
1000IU:
1000IU is a measure of immunoglobulin used in the treatment of dogs and cats that have been exposed to rabies. It is administered intravenously into the muscle, not into the blood stream. The 1000 IU Equine Rabies Immunoglobulin (ERIG) contains antibodies from horses which neutralize the virus and prevent disease transmission.
Application Insights:
Based on the application, the global equine rabies immunoglobulin (ERIG) market is segmented into category II exposure and category III exposure. Category II exposure held the largest share of over 70% in 2017. This can be attributed to high incidence of human deaths due to bites by rabid animals and increasing awareness among farmers regarding immunization against rabies.
The use of ERIG for prevention against rabid animal bite is anticipated to drive demand in category II as these products are highly effective at preventing infection when used according to manufacturer¢â‚¬â„¢s guidelines. Moreover, growing number of hospital-based clinics for Rabid Animal Bite Immunization (RABI) program across countries such as India, China and Brazil is expected to further fuel demand in this segment during next eight years.
Regional Analysis:
Asia Pacific is expected to be the fastest-growing region with a CAGR of XX% over the forecast period. The presence of high animal population and increased incidence of human rabies cases in countries such as India, China, and Indonesia are some factors anticipated to drive regional growth.
In 2017, North America accounted for a market share of 22%. The U.S.
Growth Factors:
- Increasing demand for equine rabies immunoglobulin (ERIG) due to rising incidence of rabies across the globe.
- Growing awareness about the benefits of equine rabies immunoglobulin (ERIG) among people, which is likely to boost the market growth in the near future.
- Rising number of research and development activities for new and innovative products is expected to fuel the growth of this market in coming years.
- Technological advancements in manufacturing process are projected to offer lucrative opportunities for key players operating in this market during forecast period 2017-2025
Scope Of The Report
Report Attributes
Report Details
Report Title
Equine Rabies Immunoglobulin (ERIG) Market Research Report
By Type
1500IU, 1000IU, 400IU, Other
By Application
Category II Exposure, Category III Exposure
By Companies
Serum China, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Premium Serums, Haffkine Bio-Pharmaceutical, Bharat Serums
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Equine Rabies Immunoglobulin (ERIG) Market Report Segments:
The global Equine Rabies Immunoglobulin (ERIG) market is segmented on the basis of:
Types
1500IU, 1000IU, 400IU, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Category II Exposure, Category III Exposure
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Serum China
- Lanzhou Institute of Biological Products
- Wuhan Institute of Biological Products
- Premium Serums
- Haffkine Bio-Pharmaceutical
- Bharat Serums
 Market Overview.svg)
Highlights of The Equine Rabies Immunoglobulin (ERIG) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- 1500IU
- 1000IU
- 400IU
- Other
- By Application:
- Category II Exposure
- Category III Exposure
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Equine Rabies Immunoglobulin (ERIG) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Equine rabies immunoglobulin (ERIG) is a vaccine used to prevent rabies in horses. ERIG is made from the blood of horses that have been vaccinated against rabies.
Some of the key players operating in the equine rabies immunoglobulin (erig) market are Serum China, Lanzhou Institute of Biological Products, Wuhan Institute of Biological Products, Premium Serums, Haffkine Bio-Pharmaceutical, Bharat Serums.
The equine rabies immunoglobulin (erig) market is expected to grow at a compound annual growth rate of 5.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Equine Rabies Immunoglobulin (ERIG) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Equine Rabies Immunoglobulin (ERIG) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Equine Rabies Immunoglobulin (ERIG) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Equine Rabies Immunoglobulin (ERIG) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Equine Rabies Immunoglobulin (ERIG) Market Size & Forecast, 2018-2028
4.5.1 Equine Rabies Immunoglobulin (ERIG) Market Size and Y-o-Y Growth
4.5.2 Equine Rabies Immunoglobulin (ERIG) Market Absolute $ Opportunity
Chapter 5 Global Equine Rabies Immunoglobulin (ERIG) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
5.2.1 1500IU
5.2.2 1000IU
5.2.3 400IU
5.2.4 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Equine Rabies Immunoglobulin (ERIG) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
6.2.1 Category II Exposure
6.2.2 Category III Exposure
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Equine Rabies Immunoglobulin (ERIG) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Equine Rabies Immunoglobulin (ERIG) Analysis and Forecast
9.1 Introduction
9.2 North America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
9.6.1 1500IU
9.6.2 1000IU
9.6.3 400IU
9.6.4 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
9.10.1 Category II Exposure
9.10.2 Category III Exposure
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Equine Rabies Immunoglobulin (ERIG) Analysis and Forecast
10.1 Introduction
10.2 Europe Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
10.6.1 1500IU
10.6.2 1000IU
10.6.3 400IU
10.6.4 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
10.10.1 Category II Exposure
10.10.2 Category III Exposure
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Equine Rabies Immunoglobulin (ERIG) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
11.6.1 1500IU
11.6.2 1000IU
11.6.3 400IU
11.6.4 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
11.10.1 Category II Exposure
11.10.2 Category III Exposure
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Equine Rabies Immunoglobulin (ERIG) Analysis and Forecast
12.1 Introduction
12.2 Latin America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
12.6.1 1500IU
12.6.2 1000IU
12.6.3 400IU
12.6.4 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
12.10.1 Category II Exposure
12.10.2 Category III Exposure
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Equine Rabies Immunoglobulin (ERIG) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Type
13.6.1 1500IU
13.6.2 1000IU
13.6.3 400IU
13.6.4 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Equine Rabies Immunoglobulin (ERIG) Market Size Forecast by Applications
13.10.1 Category II Exposure
13.10.2 Category III Exposure
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Equine Rabies Immunoglobulin (ERIG) Market: Competitive Dashboard
14.2 Global Equine Rabies Immunoglobulin (ERIG) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Serum China
14.3.2 Lanzhou Institute of Biological Products
14.3.3 Wuhan Institute of Biological Products
14.3.4 Premium Serums
14.3.5 Haffkine Bio-Pharmaceutical
14.3.6 Bharat Serums
